直击业绩会丨复宏汉霖CEO朱俊:打响生物类似药品牌后,再将其获得的现金流持续引流至可负担的创新

每日经济新闻
26 Mar

3月24日,复宏汉霖(HK02696)发布2024年度业绩公告,公司于报告期内实现营业收入约57.244亿元,同比增长6.1%;净利润约8.205亿元,同比增长50.3%。公司核心产品商业化销售的持续扩大成为业绩增长的重要驱动力。此外,复宏汉霖全年研发投入达到18.405亿元,同比增长28.4%。2024年,复宏汉霖的营收主要来自药物销售、向客户提供的研发服务及授权许可收入。其中,销售生物制药产品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10